Key facts
- This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for scPharmaceuticals Inc. (SCPH).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 15 Aug 2024, 16:51.
ORBIMED ADVISORS LLC - 13 Aug 2024 Form 4 Insider Report for scPharmaceuticals Inc. (SCPH)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- SCPH
- Reported as of
- 13 Aug 2024
- Net transaction value
- +$2,000,000
- SEC form
- 4
- Accepted by SEC
- 15 Aug 2024, 16:51:14 UTC
- Prior SEC filing
- 17 Jul 2024
- Next SEC filing
- 23 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl Gordon, Member of OrbiMed Advisors LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ORBIMED ADVISORS LLC filed Form 4 for scPharmaceuticals Inc. (SCPH) on 15 Aug 2024.
Change
- Previous filing in this sequence was filed on 17 Jul 2024.
- Current net transaction value: +$2,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SCPH
transaction
Common Stock
Purchase
- Transaction value
- $1,913,368
- Shares
- +478,342
- Change %
- +9%
- Price
- $4.00
- Shares after
- 5,806,670
- Date
- 13 Aug 2024
- Ownership
- See footnotes
- Footnotes
- F1, F2, F4
SCPH
transaction
Common Stock
Purchase
- Transaction value
- $86,632
- Shares
- +21,658
- Change %
- +9.4%
- Price
- $4.00
- Shares after
- 252,858
- Date
- 13 Aug 2024
- Ownership
- See footnotes
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
These shares of the Issuer's common stock were purchased in an underwritten public offering.
Footnote F2
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("OrbiMed GP") is the general partner of OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
Footnote F3
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
Footnote F4
This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.